Sign in Register

Tobramycin Sulfate (tobramycin sulfate)

Advertisement

Last reviewed · Source: First Databank (FDB) drug data

Overview

Tobramycin is an aminoglycoside antibiotic.

USES: This medication is used to prevent or treat a wide variety of bacterial infections. Tobramycin belongs to a class of drugs known as aminoglycoside antibiotics. It works by stopping the growth of bacteria.

Generic name: tobramycin sulfate
Pronunciation: (TOE-bra-MYE-sin)

Reference product & biosimilars

No reference, biosimilar or interchangeable associated with this drug.

Today’s intelligence on Tobramycin Sulfate

Intelligence content is not available yet.

Indications

The following indications are listed for Tobramycin Sulfate:

  • Bacterial Meningitis
  • Bacterial Sepsis
  • Bone Infection
  • Citrobacter Complicated Uti
  • Complicated Bacterial Infection Of Urinary Tract
  • Complicated E. Coli Uti
  • Complicated Proteus Uti
  • Complicated Uti With Pseudomonas Aeruginosa
  • E. Coli Osteomyelitis
  • E. Coli Peritonitis
  • E. Coli Septicemia
  • Enterobacter Complicated Uti
  • Enterobacter Osteomyelitis
  • Enterobacter Peritonitis
  • Enterobacter Pneumonia
  • Escherichia Coli Pneumonia
  • Gram-Negative Aerobic Bacillary Pneumonia
  • Klebsiella Complicated Uti
  • Klebsiella Pneumonia
  • Klebsiella Pneumoniae Osteomyelitis
  • Klebsiella Pneumoniae Peritonitis
  • Klebsiella Pneumoniae Septicemia
  • Neonatal Meningitis
  • Nosocomial Bacterial Pneumonia
  • Proteus Mirabilis Osteomyelitis
  • Providencia Complicated Uti
  • Pseudomonas Aeruginosa Osteomyelitis
  • Pseudomonas Aeruginosa Pneumonia
  • Pseudomonas Aeruginosa Septicemia
  • Sepsis Of Newborn
  • Serratia Complicated Uti
  • Serratia Pneumonia
  • Skin And Skin Structure E. Coli Infection
  • Skin And Skin Structure Enterobacter Infection
  • Skin And Skin Structure Klebsiella Infection
  • Skin And Skin Structure Proteus Infection
  • Skin And Skin Structure Pseudomonas Aeruginosa Infection
  • Staphylococcal Pneumonia
  • Staphylococcus Aureus Complicated Uti
  • Staphylococcus Aureus Osteomyelitis
  • Staphylococcus Aureus Skin And Skin Structure Infection
  • Synergy For Bacterial Meningitis
  • Synergy For Neonatal Meningitis
  • Synergy For Nosocomial Pneumonia Due To Pseudomonas Aeruginosa
  • Synergy For Staphylococcal Infection

Also known as: Bacteremia With Sepsis, Bacterial Sepsis Of Newborn, Bacterial Septicemia, Complicated Bacterial Urinary Tract Infection, Complicated Pseudomonas Aeruginosa Urinary Tract Infection, Complicated Staphylococcus Aureus Urinary Tract Infection, Complicated Urinary Tract Infection Due To Aerobacter, Complicated Urinary Tract Infection Due To Citrobacter, Complicated Urinary Tract Infection Due To Enterobacter, Complicated Urinary Tract Infection Due To Escherichia Coli, Complicated Urinary Tract Infection Due To Klebsiella, Complicated Urinary Tract Infection Due To Providencia, Complicated Urinary Tract Infection Due To Serratia, Complicated Urinary Tract Proteus Species Infection, Complicated Uti Due To Citrobacter Species, Complicated Uti Due To E. Coli, Complicated Uti Due To Enterobacter Species, Complicated Uti Due To Klebsiella Species, Complicated Uti Due To Proteus Species, Complicated Uti Due To Providencia Species, Complicated Uti Due To Pseudomonas Aeruginosa, Complicated Uti Due To Serratia Species, Complicated Uti Due To Staphylococcus Aureus, E. Coli Pneumonia, E. Coli Sepsis, Escherichia Coli Sepsis, Escherichia Coli Septicemia, Hospital-Acquired Bacterial Pneumonia, Infection Of The Lungs Due To Enterobacter, Infection Of The Lungs Due To Pseudomonas Aeruginosa, Infection Of The Lungs Due To Serratia Species, Neonatal Sepsis, Osteomyelitis Due To Aerobacter, Osteomyelitis Due To E. Coli, Osteomyelitis Due To Enterobacter, Osteomyelitis Due To Enterobacter Species, Osteomyelitis Due To Escherichia Coli, Osteomyelitis Due To Klebsiella Pneumoniae, Osteomyelitis Due To Proteus Mirabilis, Osteomyelitis Due To Pseudomonas Aeruginosa, Osteomyelitis Due To Staphylococcus Aureus, Osteomyelitis Due To Staphylococcus Pyogenes Aureus, Peritonitis Due To Aerobacter, Peritonitis Due To Enterobacter, Peritonitis Due To Escherichia Coli, Peritonitis Due To Klebsiella Pneumoniae, Pneumonia Due To E. Coli, Pneumonia Due To Escherichia Coli, Pneumonia Due To Gram-Negative Organism, Pneumonia Due To Klebsiella Species, Pneumonia Due To Klebsiella Spp., Pneumonia Due To Pseudomonas Aeruginosa, Pneumonia Due To Serratia Species, Pneumonia Due To Serratia Spp., Pneumonia Due To Staphylococcus Species, Pneumonia Due To Staphylococcus Spp., Pyogenic Bone Infection Due To E. Coli, Pyogenic Bone Infection Due To Enterobacter, Pyogenic Bone Infection Due To Klebsiella Pneumoniae, Pyogenic Bone Infection Due To Proteus Mirabilis, Pyogenic Bone Infection Due To Pseudomonas Aeruginosa, Pyogenic Bone Infection Due To Staphylococcus Aureus, Sepsis Due To Klebsiella Pneumoniae, Sepsis Due To Pseudomonas Aeruginosa, Septicemia Due To Klebsiella Pneumoniae, Septicemia Due To Pseudomonas Aeruginosa, Skin And Skin Soft Tissue Enterobacter Infection, Skin And Skin Soft Tissue Escherichia Coli Infection, Skin And Skin Soft Tissue Infection Due To Aerobacter, Skin And Skin Soft Tissue Infection Due To Enterobacter, Skin And Skin Soft Tissue Infection Due To Klebsiella, Skin And Skin Soft Tissue Proteus Infection, Skin And Skin Soft Tissue Pseudomonas Aeruginosa Infection, Skin And Skin Soft Tissue Staphylococcus Aureus Infection.

Dosing

In patients with impaired renal function, doses and/or frequency of administration of tobramycin must be modified in response to serum concentrations of the drug and the degree of renal impairment. There are various methods to determine dosage and a wide variation in dosage recommendations for these patients. However, even when one of these methods is used, peak and trough serum concentrations of the drug should be monitored, especially in patients with changing renal function.

The manufacturers recommend an initial loading dose of 1 mg/kg with subsequent dosage adjusted either by using reduced doses at 8-hour intervals or using usual doses at prolonged intervals. If serum concentrations of tobramycin are unavailable, dosage adjustments in patients with renal impairment may be guided by creatinine clearance or serum creatinine concentrations because these values correlate with the half-life of tobramycin. The manufacturers' information should be consulted for a nomogram based on creatinine clearance or serum creatinine concentrations that can be used to determine the amount of reduced dose that can be given at the usual dosing intervals. Alternatively, if creatinine clearance is not available and the patient's condition is stable, the manufacturers state that the usual dosage of the drug can be given at a reduced dosage frequency that is calculated by multiplying the patient's steady-state serum creatinine (in mg/dL) by 6. Many clinicians recommend the dosing method of Sarubbi and Hull, which is based on corrected creatinine clearance. (See Dosage and Administration: Dosage in Renal Impairment, in the Aminoglycosides General Statement 8:12.02.)

In adults with renal failure undergoing hemodialysis, some clinicians recommend supplemental doses of 50-75% of the initial loading dose at the end of each dialysis period. Serum tobramycin concentrations should be monitored in dialysis patients and dosage adjusted as needed to maintain desired serum concentrations.

Drug interactions

There is no enhanced messaging for this drug.

Contraindications

There is no enhanced messaging for this drug.

Adverse reactions

There is no enhanced messaging for this drug.

Precautions

No enhanced messaging available.

ICD codes

No ICD codes are available for this drug.

Formulary status

Search health-plan coverage for this drug by ZIP code.

Enter a 5-digit ZIP code. Searching does not change your profile.

Enter a ZIP code to view available health plans.

Last reviewed · Source: First Databank (FDB) drug data